[
  {
    "ts": "2025-11-03T05:31:45+00:00",
    "headline": "5 Insightful Analyst Questions From Keurig Dr Pepper’s Q3 Earnings Call",
    "summary": "Keurig Dr Pepper’s third quarter was marked by robust revenue expansion and a strong market response, with management attributing the outperformance to continued momentum across its core beverage and coffee businesses. CEO Tim Cofer highlighted that “net sales accelerated in Q3,” driven by solid gains in both U.S. Refreshment Beverages and international markets, as well as successful pricing actions in the coffee segment. Additionally, the company maintained its operating margins despite inflati",
    "url": "https://finance.yahoo.com/news/5-insightful-analyst-questions-keurig-053145177.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "d5fbe316-efab-3b81-a592-ae0179935316",
      "content": {
        "id": "d5fbe316-efab-3b81-a592-ae0179935316",
        "contentType": "STORY",
        "title": "5 Insightful Analyst Questions From Keurig Dr Pepper’s Q3 Earnings Call",
        "description": "",
        "summary": "Keurig Dr Pepper’s third quarter was marked by robust revenue expansion and a strong market response, with management attributing the outperformance to continued momentum across its core beverage and coffee businesses. CEO Tim Cofer highlighted that “net sales accelerated in Q3,” driven by solid gains in both U.S. Refreshment Beverages and international markets, as well as successful pricing actions in the coffee segment. Additionally, the company maintained its operating margins despite inflati",
        "pubDate": "2025-11-03T05:31:45Z",
        "displayTime": "2025-11-03T05:31:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/c9c869364179c598dca88aeda191507a",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "KDP Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wmJ2bDLddulGaOUARJOC7Q--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/c9c869364179c598dca88aeda191507a.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nZuu3ToCWFLlAeDR6I6h4g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/c9c869364179c598dca88aeda191507a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/5-insightful-analyst-questions-keurig-053145177.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-insightful-analyst-questions-keurig-053145177.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KDP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T20:45:00+00:00",
    "headline": "Kimberly-Clark to Buy Tylenol Maker Kenvue. Why the Stock Market Hates the Deal.",
    "summary": "Kimberly-Clark  is buying Tylenol maker  Kenvue  for nearly $50 billion.  The cash-and-stock transaction, announced Monday, values Kenvue at an enterprise value of about $48.7 billion, including debt.  Under the terms of the deal, Kenvue shareholders will receive $21.01 a share, based on Kenvue’s closing price of $14.37 on Friday.",
    "url": "https://www.barrons.com/articles/kmb-stock-price-kenvue-deal-kimberly-clark-tylenol-bcbd0ec3?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "88ce0b9d-2216-33bf-ae82-30bebe572b3a",
      "content": {
        "id": "88ce0b9d-2216-33bf-ae82-30bebe572b3a",
        "contentType": "STORY",
        "title": "Kimberly-Clark to Buy Tylenol Maker Kenvue. Why the Stock Market Hates the Deal.",
        "description": "",
        "summary": "Kimberly-Clark  is buying Tylenol maker  Kenvue  for nearly $50 billion.  The cash-and-stock transaction, announced Monday, values Kenvue at an enterprise value of about $48.7 billion, including debt.  Under the terms of the deal, Kenvue shareholders will receive $21.01 a share, based on Kenvue’s closing price of $14.37 on Friday.",
        "pubDate": "2025-11-03T20:45:00Z",
        "displayTime": "2025-11-03T20:45:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/88ce0b9d-2216-33bf-ae82-30bebe572b3a/kimberly-clark-to-buy-tylenol.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/4c5a1d62bedf8bbcce69ec4d131564a0",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4VjAtBmJXPcK9DM4yseugg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/4c5a1d62bedf8bbcce69ec4d131564a0.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4W54wQaQ4UUvA3TyVV3W6Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/4c5a1d62bedf8bbcce69ec4d131564a0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/kmb-stock-price-kenvue-deal-kimberly-clark-tylenol-bcbd0ec3?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "KDP"
            },
            {
              "symbol": "KHC"
            },
            {
              "symbol": "KMB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]